CDX2 and colorectal carcinoma: Accordingly, the proposed predictive value of CDX2 may be context‐dependent; however, it is difficult to compare adjuvant treatment for stage III with largely palliative treatment for stage IV, and many other factors are likely to have an impact on the survival of patients with stage IV CRC.